More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
US FDA Approves Generic Loteprednol Etabonate Drops from India’s Lupin for Seasonal Allergy
Author: Jennie Crabbe
Indian drugmaker Lupin announced Dec. 27 that the US FDA had approved its abbreviated new drug application for loteprednol etabonate ophthalmic suspension, 0.2%, a generic equivalent of Bausch + Lomb’s Alrex.
Loteprednol etabonate drops are indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Lupin, with 15 locations worldwide, said the product would be manufactured at its facility in Pithampur, India.
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.